CorVel Corporation research snapshot
CRVL AI stock analysis reads CorVel Corporation as the only independent, publicly traded claims management and healthcare cost containment company, serving self-insured employers, carriers, third-party administrators, and government agencies. At the August 4, 2026 data cutoff, the quoted price was $60.51 with a market capitalization near $3.09 billion, verified as $60.51 times about 51.01 million shares. For fiscal year 2026 (ended March 31, 2026), revenue rose 7% to $958.53 million and net income rose about 16% to $110.34 million with EPS of $2.14. The balance sheet held about $233 million of cash with no borrowings, and the company repurchased $20.1 million of stock in the fourth quarter. The stock is down about 35% from its 52-week high near $93.71 after a multi-quarter decline, and the next quarterly report is scheduled for August 5, 2026. This page uses scenarios, technical levels, and source-backed facts. It is informational research and not investment advice.
Current price
$60.51 at the August 3, 2026 close, up 0.45 or 0.75% from the $60.06 July 31 close, within a session range of $60.37 to $61.83 after opening at $60.97
Market cap
$3.09 billion
AI score
55 / 100
Rating
High-quality, debt-free claims management niche leader at a de-rated multiple, still in a price downtrend with a CEO transition, limited sell-side coverage, and thin near-term catalysts
Trend status
Downtrend from the 52-week high near $93.71, now stabilizing in a $56 to $66 range below the 200-day moving average near $62
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | CorVel provides workers compensation claims management, medical bill review, case management, network solutions, and healthcare cost containment to employers, carriers, TPAs, and government agencies. FY2026 revenue was $958.53 million with net income of $110.34 million and EPS of $2.14. | Medium-high |
| Moat | The moat is built on 35+ years of claims data, the proprietary CareMC platform, independence from insurance carriers, complex regulatory workflows, and long-standing client relationships, but most direct competitors are private and hard to benchmark. | Medium |
| Management | Sarah Scott was appointed CEO and President effective July 1, 2026, succeeding Michael G. Combs, who moved to Executive Chair. The transition adds execution risk. Insiders owned about 2.21% per StockAnalysis.com and institutions about 53.97%, with a $20.1 million buyback in Q4 FY2026. | Medium-low |
| Financial trend | Revenue grew 7.03% to $958.53 million in FY2026 and net income grew about 16% to $110.34 million. The balance sheet held about $233 million of cash with no borrowings, and free cash flow was $110.28 million, cross-validated between StockAnalysis.com and the CorVel earnings release. | Medium-high |
| Valuation | At the $60.51 cutoff price, trailing PE was about 28x, P/FCF about 28.2x, and EV/EBITDA about 16.6x. The multiple is down sharply from 2025 levels but still prices in sustained high single digit to low double digit growth, so the margin of safety is modest. | Medium |
| Technical trend | The stock is down about 30.7% over 52 weeks and trades below its 200-day moving average near $62. RSI near 46 to 49 and ADX near 11 point to a weak, choppy trend rather than a confirmed reversal as of the cutoff. | Medium |
| Risk level | The thesis can fail if workers comp claims volume declines with a softer labor market, private competitors undercut on price or technology, healthcare regulation shifts unfavorably, the CEO transition disrupts execution, or growth decelerates enough to compress the multiple further. | Medium-high |
| AI confidence | Medium data confidence for verified financials, balance sheet, buyback data, and technical indicators. Lower confidence for competitive positioning and forward returns given limited analyst coverage and private competitor dynamics. | Medium |
| Investment certainty | Medium certainty because the page gives a framework, not a personalized buy or sell instruction. The August 5, 2026 earnings report and evidence on organic growth and margin trajectory will determine whether the bearish or bullish case becomes more likely. | Medium |
CRVL AI stock forecast
The CRVL AI stock forecast uses scenario ranges around the $60.51 cutoff price rather than a point target. It does not claim that AI can predict a specific future price. The bullish case requires evidence that revenue growth re-accelerates and margins expand under the new CEO; the base case assumes steady high single digit growth with the stock consolidating near current levels; the bearish case assumes growth decelerates, the CEO transition disrupts execution, or the multiple compresses further.
$75 to $90
More likely if CorVel shows sustained double digit EPS growth, CERIS health division and CorVel Connected adoption expand, gross margin holds above 24%, the CEO transition goes smoothly, and the stock reclaims and holds above the 200-day moving average near $62 with rising volume.
$60 to $72
More likely if revenue grows around 7% to 10% in FY2027, EPS grows in the mid teens, margins stay stable, the August 5, 2026 report is in line, and the stock grinds within the $56 to $66 range that has contained price action since June 2026.
$44 to $55
More likely if workers comp claims volume declines, growth decelerates below the historical rate, the CEO transition causes execution drift, private competitors gain share, the stock breaks below the June 2026 low near $56.29, or the August 5 report disappoints.
CRVL AI technical analysis
CRVL AI technical analysis starts from the $60.51 close on August 3, 2026. The stock is in a longer-term downtrend from the 52-week high near $93.71 but has spent the last two months in a $56 to $66 range. Price sits below its 200-day moving average near $62.25 and just below its 20-day and 50-day moving averages near $61.38 and $61.02. RSI near 46 to 49 is neutral, and ADX near 11 signals a weak trend. Because this static page does not fetch request-time chart data, moving averages and momentum should be confirmed in a charting tool before use.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $60.51 | August 3, 2026 close, up 0.45 or 0.75% from the $60.06 July 31 close, within a session range of $60.37 to $61.83. |
| Near support | $56.29 to $58.00 | The June 2026 low near $56.29 and the surrounding congestion zone. Treat as a planning band, not a guaranteed floor. |
| 50-day moving average | $61.01 to $61.02 | Barchart and StockAnalysis.com both reported the 50-day moving average near $61.0 on August 3, 2026. Price is just below this level. |
| 200-day moving average | $62.25 | Barchart and StockAnalysis.com both reported the 200-day moving average near $62.25. A sustained reclaim would improve the medium-term picture. |
| Near resistance | $63.00 to $66.47 | The July 29 high near $63.00 and the July 2 intraday high near $66.47 cap the range. A close above this zone would mark the first higher high in months. |
| 52-week high resistance | $93.71 | The 52-week high. Recapturing it would require a full trend reversal and sustained fundamental acceleration, which is not the base case. |
| Momentum | Neutral, RSI near 46 to 49 with weak ADX | Barchart reported 14-day RSI near 49.06 and StockAnalysis.com near 46.07 on August 3, 2026. ADX near 11 signals a weak trend, so momentum is choppy rather than directional. |
| Volume | Below-average volume | The August 3 volume of about 118,972 was below the 20-day average near 157,000 to 162,000 shares, suggesting reduced conviction in the current move. |
| Volatility | 14-day ATR near $1.91, about 3.2% of price | Historic volatility near 26.6% at 14 days and about 35% at 50 days. Position sizing should tolerate daily swings of a few dollars for this mid-cap ticker. |
| Invalidation | Close below $56.29 | A decisive close below the June 2026 low near $56.29 would weaken the range thesis and open the path toward the 52-week low of $44.83. |
CRVL AI trading strategy
The CRVL AI trading strategy is a rules-based research framework, not personalized advice. It pairs range-based price action with fundamental monitoring of organic growth, margins, and the CEO transition, plus clear invalidation levels and the August 5, 2026 earnings event.
Wait for CRVL to reclaim and hold the 200-day moving average near $62.25, then close above the $63.00 to $66.47 resistance zone on above-average volume before treating the downtrend as broken.
A close back below $60 or a failed breakout above $66.47 should invalidate the setup. Respect the June low near $56.29 as the planning floor.
Within the $56.29 to $66.47 range, look for entries near the lower third around $57 to $59 with RSI divergence, and reduce exposure near the upper third around $64 to $66 unless the trend has turned.
Do not average down without a predefined maximum loss, and watch the August 5, 2026 earnings release because a headline miss can break the range.
Track the evidence that matters most for healthcare cost containment: organic revenue growth, gross and operating margins, CERIS and CorVel Connected adoption, buyback pace, insider activity, and commentary from the new CEO on the August 5 call.
Reduce confidence if price moves are driven by CEO transition headlines or sector rotation without matching financial evidence, or if growth decelerates below the high single digit range.
Investment research summary
CorVel helps employers, insurers, and government agencies manage and contain healthcare costs tied to workplace injuries and other claims, using technology-driven claims management, bill review, case management, network services, and payment accuracy tools. Customers pay because lower claims cost and faster recovery translate directly into financial outcomes for them.
The moat comes from 35+ years of claims data, the proprietary CareMC platform, independence from insurance carriers, the complexity of state-by-state regulatory workflows, and long-standing client relationships that create switching costs when replacing a claims administrator.
The thesis can fail if workers comp claims volume declines in a soft labor market, private competitors such as Sedgwick and Gallagher Bassett out-invest in technology and AI, healthcare payment regulation shifts, the CEO transition from Michael Combs to Sarah Scott disrupts execution, or growth decelerates enough to compress the valuation multiple.
Founder V. Gordon Clemons built the company over decades, and Michael G. Combs led it for years before transitioning to Executive Chair on July 1, 2026, when Sarah Scott became CEO and President. The first leadership change in a long time warrants monitoring for strategic continuity, talent retention, and capital allocation discipline.
The shift toward self-insurance, proactive payment accuracy, and AI-driven claims processing is a secular tailwind that CorVel is positioning around with CorVel Connected and CERIS, but workers comp volume is tied to employment levels, which introduces cyclicality.
At 28x trailing earnings, about 28.2x P/FCF, and about 16.6x EV/EBITDA with a debt-free balance sheet and about 30.8% ROE, the valuation is reasonable but not cheap. The market is pricing in continued mid-teens EPS growth, so the margin of safety is modest if growth disappoints or the multiple compresses further.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CRVL price | $60.51 close on August 3, 2026, up 0.75%, within a session range of $60.37 to $61.83 | StockAnalysis.com real-time quote and price history | August 4, 2026 |
| Market capitalization | $3.09 billion, verified as $60.51 x about 51.01 million shares with 0.11% deviation | StockAnalysis.com statistics and financial_rigor.py market cap verification | August 4, 2026 |
| Enterprise value | $2.91 billion | StockAnalysis.com statistics | August 4, 2026 |
| Shares outstanding / float | 51.01 million shares outstanding; 31.12 million float | StockAnalysis.com statistics | August 4, 2026 |
| FY2026 revenue | $958.53 million, up 7.03% from $895.59 million in FY2025 | CorVel earnings release and StockAnalysis.com financials | August 4, 2026 |
| FY2026 net income / EPS | $110.34 million net income, up about 16%; diluted EPS $2.14, up 17% from $1.83 | CorVel earnings release and StockAnalysis.com financials | August 4, 2026 |
| FY2026 gross profit / margin | $232.86 million gross profit at a 24.29% margin | CorVel earnings release and StockAnalysis.com financials | August 4, 2026 |
| Q4 FY2026 results | Revenue $248.55 million, up 7.36%; EPS $0.61, up 20% from $0.51 | CorVel earnings release | August 4, 2026 |
| Cash and borrowings | About $233.07 million in cash with no borrowings as of March 31, 2026 | CorVel earnings release and StockAnalysis.com balance sheet | August 4, 2026 |
| Free cash flow | Operating cash flow $155.64 million, capex $45.36 million, free cash flow $110.28 million | StockAnalysis.com cash flow statement | August 4, 2026 |
| Buybacks | Repurchased $20.1 million of common stock in Q4 FY2026 | CorVel earnings release | August 4, 2026 |
| 5-year revenue trend | FY2022 $646.23M, FY2023 $718.56M, FY2024 $795.31M, FY2025 $895.59M, FY2026 $958.53M | StockAnalysis.com financials | August 4, 2026 |
| Valuation multiples | PE 28.07, P/S 3.25, P/B 7.76, P/FCF 28.24, EV/EBITDA 16.63, EV/FCF 26.38, EV/Sales 3.04 | StockAnalysis.com statistics | August 4, 2026 |
| Profitability metrics | ROE 30.81%, ROA 15.05%, ROIC 61.15%, Altman Z-Score 15.07, Piotroski F-Score 6 | StockAnalysis.com statistics | August 4, 2026 |
| Balance sheet position | Debt/Equity 0.07, Debt/EBITDA 0.16, current ratio 2.03, net cash about $204.97 million or $4.02 per share | StockAnalysis.com statistics | August 4, 2026 |
| Ownership | Insiders about 2.21%, institutions about 53.97%, float 31.12 million shares | StockAnalysis.com statistics | August 4, 2026 |
| Short interest | 1.10 million shares, 2.16% of shares outstanding, 3.54% of float, days to cover 4.67 | StockAnalysis.com statistics | August 4, 2026 |
| 52-week price range | $44.83 to $93.71, down about 30.7% over 52 weeks | StockAnalysis.com quote and price history | August 4, 2026 |
| Technical indicators | 50-day MA $61.01 to $61.02, 200-day MA $62.25, RSI 46.07 to 49.06, ADX near 11, 14-day ATR near $1.91 | StockAnalysis.com statistics and Barchart technical analysis | August 4, 2026 |
| Next earnings date | August 5, 2026, before market open, with a live webcast at 11:30 AM ET | StockAnalysis.com and CorVel webcast announcement | August 4, 2026 |
| CEO transition | Sarah Scott appointed CEO and President effective July 1, 2026; Michael G. Combs transitioned to Executive Chair | CorVel appointment announcement | August 4, 2026 |
This CRVL AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of August 4, 2026, may be incomplete, and can be wrong if new filings, market prices, company events, or macro conditions change. The stock has limited sell-side coverage, and competitive data is affected by the fact that most direct competitors are private. Confirm all figures with primary sources before making decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
